Rejuran, polynucleotides and PDRN: what each one is
· AVELIA
In a nutshell
Rejuran is a brand of injectable polynucleotides, from the Korean laboratory PharmaResearch. «Polynucleotides» (PN) and «PDRN» are two names for DNA-derived molecules that are often used as if they were the same thing, and they are not. At AVELIA we use Rejuran polynucleotides.
Polynucleotides (PN) and PDRN
A 2025 scientific review compares the two groups: polynucleotides (PN) have longer chains and form a more viscous structure; PDRN (polydeoxyribonucleotide) has a lower molecular weight and is less viscoelastic. The same review notes that there is confusion in how they are named.
A 2024 systematic review found promising results for injectable polynucleotides on wrinkles, texture and elasticity, and warned that the studies included were of low or moderate quality.
What we use at AVELIA and what for
Rejuran polynucleotides, to gradually improve skin quality: the aim is to regenerate, not to add volume. There are three treatments, one per area: the face, the eye contour and the neck.
What Rejuran is not
- It is not a filler: it does not add volume or change proportions.
- It is not the same as treating the tear trough with hyaluronic acid: Rejuran periocular works on the quality of the skin of the eye contour; hyaluronic acid supports the trough when indicated.
- It is not immediate: results are usually noticed progressively over the following weeks and improve with the recommended course of sessions.
Who carries it out and where
Treatments are carried out by Natalia, founder of AVELIA and a nurse specialising in aesthetics, who assesses the indication before starting. We are next to Turó Park, in the Sant Gervasi-Galvany neighbourhood: Carrer del Mestre Nicolau, 16, Sarrià-Sant Gervasi, 08021 Barcelona.
Sources
- PharmaResearch, manufacturer of Rejuran
- Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives, Pharmaceutics, 2025
- The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review, 2024
- AVELIA catalogue and validated clinical texts (28/10/2026)